IceCure Medical (ICCM) Net Income towards Common Stockholders (2020 - 2026)

IceCure Medical (ICCM) has reported Net Income towards Common Stockholders for 7 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 19.12% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $15.7 million (up 1.14% YoY), while the FY2025 annual figure was -$11.8 million, up 49.19% from the prior year.
• Net Income towards Common Stockholders rose to $4.3 million in Q1 2026 per ICCM's latest filing, from $4.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $4.4 million in Q1 2022 and bottomed at -$46.9 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$2.0 million across 5 years, with a median of $4.1 million in 2023.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 270.91% in 2022 and fell as far as 53.49% in 2022.
• IceCure Medical's Net Income towards Common Stockholders stood at -$46.9 million in 2022, then gained by 0.78% to -$46.5 million in 2023, then jumped by 109.52% to $4.4 million in 2024, then fell by 4.72% to $4.2 million in 2025, then increased by 1.38% to $4.3 million in 2026.
• Business Quant data shows ICCM's Net Income towards Common Stockholders at $4.3 million in Q1 2026, $4.2 million in Q4 2025, and $3.8 million in Q3 2025.